Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations · Full text

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.1K citations

Medicine, Bronchial Neoplasm, Advanced Alk +8